CN119770645A - 用于诊断和/或预测痴呆症的肾上腺髓质素和抗肾上腺髓质素结合物在治疗或预防痴呆症中的应用 - Google Patents

用于诊断和/或预测痴呆症的肾上腺髓质素和抗肾上腺髓质素结合物在治疗或预防痴呆症中的应用 Download PDF

Info

Publication number
CN119770645A
CN119770645A CN202411684173.XA CN202411684173A CN119770645A CN 119770645 A CN119770645 A CN 119770645A CN 202411684173 A CN202411684173 A CN 202411684173A CN 119770645 A CN119770645 A CN 119770645A
Authority
CN
China
Prior art keywords
adm
dementia
adrenomedullin
subject
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411684173.XA
Other languages
English (en)
Chinese (zh)
Inventor
奥利·梅兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sphingotec GmbH
Original Assignee
Sphingotec GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sphingotec GmbH filed Critical Sphingotec GmbH
Publication of CN119770645A publication Critical patent/CN119770645A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
CN202411684173.XA 2018-02-08 2019-02-07 用于诊断和/或预测痴呆症的肾上腺髓质素和抗肾上腺髓质素结合物在治疗或预防痴呆症中的应用 Pending CN119770645A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18155682 2018-02-08
EP18155682.0 2018-02-08
PCT/EP2019/052982 WO2019154900A1 (en) 2018-02-08 2019-02-07 Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
CN201980012542.1A CN111902721B (zh) 2018-02-08 2019-02-07 用于诊断和/或预测痴呆症的肾上腺髓质素和抗肾上腺髓质素结合物在治疗或预防痴呆症中的应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980012542.1A Division CN111902721B (zh) 2018-02-08 2019-02-07 用于诊断和/或预测痴呆症的肾上腺髓质素和抗肾上腺髓质素结合物在治疗或预防痴呆症中的应用

Publications (1)

Publication Number Publication Date
CN119770645A true CN119770645A (zh) 2025-04-08

Family

ID=61188647

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411684173.XA Pending CN119770645A (zh) 2018-02-08 2019-02-07 用于诊断和/或预测痴呆症的肾上腺髓质素和抗肾上腺髓质素结合物在治疗或预防痴呆症中的应用
CN201980012542.1A Active CN111902721B (zh) 2018-02-08 2019-02-07 用于诊断和/或预测痴呆症的肾上腺髓质素和抗肾上腺髓质素结合物在治疗或预防痴呆症中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980012542.1A Active CN111902721B (zh) 2018-02-08 2019-02-07 用于诊断和/或预测痴呆症的肾上腺髓质素和抗肾上腺髓质素结合物在治疗或预防痴呆症中的应用

Country Status (12)

Country Link
US (2) US20210302440A1 (cg-RX-API-DMAC7.html)
EP (1) EP3749959A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021513077A (cg-RX-API-DMAC7.html)
KR (1) KR102717599B1 (cg-RX-API-DMAC7.html)
CN (2) CN119770645A (cg-RX-API-DMAC7.html)
AU (1) AU2019219071A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020014940A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090736A1 (cg-RX-API-DMAC7.html)
IL (1) IL276564A (cg-RX-API-DMAC7.html)
MX (1) MX421834B (cg-RX-API-DMAC7.html)
SG (1) SG11202006686SA (cg-RX-API-DMAC7.html)
WO (1) WO2019154900A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4110372A1 (en) * 2020-02-26 2023-01-04 PAM Theragnostics GmbH Use of peptidylglycine alpha-amidating monooxygenase (pam) for therapeutic purpose
EP3871689A1 (en) * 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
JP2023515981A (ja) 2020-02-26 2023-04-17 ペーアーエム セラノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング ペプチジルグリシンαアミド化モノオキシゲナーゼ(PAM)を決定する方法および診断目的でのその使用
US20210285949A1 (en) 2020-03-16 2021-09-16 Sphingotec Gmbh Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
EP4680966A1 (en) 2023-03-17 2026-01-21 PAM Theragnostics GmbH Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose
WO2025133203A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Compounds and methods for a long-lasting pam
WO2025133225A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Pharmaceutical combination of peptide-gly and peptidylglycine alpha-amidating monooxygenase (pam)
WO2026099249A1 (en) 2024-11-05 2026-05-15 Pam Theragnostics Gmbh Modified and unmodified peptidylglycine alpha-amidating monooxygenase (pam) for use in subjects having increased amyloid-beta and/or phospho-tau-protein load and/or neuroinflammation
WO2026099243A1 (en) 2024-11-05 2026-05-15 Pam Theragnostics Gmbh Modified and unmodified peptidyl-glycine alpha-amidating monooxygenase (pam) for use in the treatment or prevention of cerebral hypoperfusion for the improvement of cerebral blood flow (cbf)
WO2026132535A1 (en) 2024-12-20 2026-06-25 B.R.A.H.M.S Gmbh Pro-adrenomedullin and fragment(s) thereof for diagnosis and/or prognosis of a central nervous system inflammation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
CN1628126A (zh) 2001-08-30 2005-06-15 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
AU2005287557B2 (en) 2004-09-21 2011-10-13 Biontech Ag Use of microproteins as tryptase inhibitors
DE102005036094A1 (de) * 2005-08-01 2007-02-08 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen
US20090306227A1 (en) 2005-08-31 2009-12-10 Toshiyuki Ioka Tablet for removing tongue coating
DE102006027818A1 (de) * 2006-06-16 2007-12-20 B.R.A.H.M.S. Aktiengesellschaft In vitro Multiparameter-Bestimmungsverfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
DE102006060112A1 (de) 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
WO2009095454A2 (de) * 2008-02-01 2009-08-06 Brahms Aktiengesellschaft Verfahren zur identifizierung von therapiebedürftigen patienten mit leichten kognitiven störungen und die behandlung derartiger patienten
NZ592591A (en) 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
CA2772162C (en) 2009-08-27 2018-05-22 Covagen Ag Anti-il-17a fynomers and medical uses thereof
BR112012014417B1 (pt) 2009-12-14 2021-11-09 Scil Proteins Gmbh Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina
AU2011263786B2 (en) 2010-06-08 2014-11-13 Astrazeneca Ab Tear lipocalin muteins binding IL-4 R alpha
FR2964103B1 (fr) * 2010-08-30 2018-11-23 Universite D'aix-Marseille Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament
BR112014011670B1 (pt) * 2011-11-16 2021-05-25 Adrenomed Ag anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou um arcabouço de proteína não-igg anti-adm que se liga à adrenomedulina e formulação farmacêutica
US9140696B2 (en) 2011-11-16 2015-09-22 Adrenomed Ag Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
US20160230227A1 (en) * 2012-12-21 2016-08-11 The New York Stem Cell Foundation Methods of treating alzheimer's disease
CN109716136B (zh) * 2016-07-08 2023-09-22 斯弗因高泰克有限公司 肾上腺髓质素用于评估急性心力衰竭患者的充血

Also Published As

Publication number Publication date
KR102717599B1 (ko) 2024-10-14
CN111902721B (zh) 2024-12-13
MX421834B (es) 2025-03-14
IL276564A (en) 2020-09-30
CA3090736A1 (en) 2019-08-15
KR20200135947A (ko) 2020-12-04
RU2020129154A (ru) 2022-03-10
CN111902721A (zh) 2020-11-06
MX2020008345A (es) 2020-09-25
JP2024001208A (ja) 2024-01-09
WO2019154900A1 (en) 2019-08-15
US20210302440A1 (en) 2021-09-30
JP2021513077A (ja) 2021-05-20
BR112020014940A2 (pt) 2020-12-08
EP3749959A1 (en) 2020-12-16
RU2020129154A3 (cg-RX-API-DMAC7.html) 2022-03-10
US20230221339A1 (en) 2023-07-13
AU2019219071A1 (en) 2020-07-30
SG11202006686SA (en) 2020-08-28

Similar Documents

Publication Publication Date Title
CN111902721B (zh) 用于诊断和/或预测痴呆症的肾上腺髓质素和抗肾上腺髓质素结合物在治疗或预防痴呆症中的应用
JP7654597B2 (ja) 急性心不全に罹患している対象におけるうっ血を評価するためのアドレノメデュリン
JP6336911B2 (ja) アドレノメジュリンアッセイおよび成熟アドレノメジュリンの測定方法
JP2025530718A (ja) 抗タウmtbr抗体、ならびにタウの切断された断片の検出方法およびその用途
JP6812521B2 (ja) クロモグラニンaを検出するための免疫アッセイ法および抗体
US20220268761A1 (en) Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
CN116348769A (zh) 用于检测tau蛋白病或淀粉样蛋白形成性疾病的基于血液的测定
US20250020669A1 (en) Methods for detecting neurofilament light chain in plasma and cerebrospinal fluid
JPWO2011045945A1 (ja) アミロイドβのターン構造を認識する抗体
EP3861352A1 (en) Novel biomarker for alzheimer's disease in human
KR20220145897A (ko) 쇼크의 치료 또는 예방에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드
JP2023516615A (ja) ショックを患っている患者におけるnt-adm抗体治療法ガイダンス、モニタリング、及び層別化のためのdpp3
JP2023516171A (ja) ADM-Gly/バイオADM比が閾値を超える患者においてADM-GlyからバイオADMへの転移を促進するための遊離N末端に結合する抗ADM抗体およびビタミンCとの組合せ
RU2811309C2 (ru) Адреномедуллин (adm) для диагностики и/или прогнозирования деменции и антиадреномедуллин-связующий агент для применения в терапии или профилактике деменции
CN120129835A (zh) 以mmp12为指标的免疫介导的炎症性疾病的诊断、以及基于抑制mmp12的免疫介导的炎症性疾病的治疗用药物
HK40034157A (en) Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
HK40121614A (en) Adrenomedullin for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
EP3267197B1 (en) Method and kit for the detection of pancreatic dysfunction
RU2776811C2 (ru) Мониторинг терапии при лечении связывающим веществом против адреномедуллина (adm)
CN119604526A (zh) 用于治疗或预防休克的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架
US20210041468A1 (en) Neonatal hypoxic-ischemic encephalopathy severity determining method and prognosis predicting method
HK40096066A (en) Blood-based assay for detecting tauopathy or amyloidogenic disease
EA049359B1 (ru) Анализ проб, полученных из крови, для обнаружения таупатии или амилоидогенного заболевания
HK40005377B (en) Adrenomedullin for assessing congestion in a subject with acute heart failure
HK1202624B (en) Adrenomedullin assays and methods for determining mature adrenomedullin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40121614

Country of ref document: HK